Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Europe’s Newest Biotech – Valneva – Formed As Intercell And Vivalis Marry

This article was originally published in The Pink Sheet Daily

Executive Summary

One of the few remaining independent biotech vaccine developers in Europe, Austria's Intercell, is to join forces with France's Vivalis in a proposed merger valued at $174 million to create a pipeline spanning from antibodies to vaccines.

You may also be interested in...

European Notebook: Revolutionary Change Needed for European Biotech; CHMP Releases Opinions Agenda; Growing Interest In Biosimilars

Radical change urged to help Europe compete in biotech; CHMP becomes less secretive over its meeting agendas; Almirall restructures its European business and buys U.S. dermatology business; biosimilar biologics companies, Almotech and Samsung Bioepis, target Europe.

French Biotech Valneva Raises $51 Mil. And Aims For Profitability In 2015

The new European biotech aims to become a profitable niche player focused on anti-infective vaccines and antibodies in 2015.

Deals Of The Week: Pfizer/Halozyme, Celgene/Sutro Biopharma, Amgen/ImmunoGen

The week before Christmas proved to be an extraordinarily busy one for biopharmaceutical business development, highlighted by a Pfizer deal to enhance delivery of its biologics, an ALS research consortium led by Biogen Idec and the merger of two European companies, creating vaccine- and antibody-focused Valneva.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts